TNXP - Tonix Pharmaceuticals Holding Corp.
NASDAQ
->
Healthcare
->
Biotechnology
Chatham,
United States
Type: Equity
TNXP price evolution
TNXP
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $4.16 | $7.05 | $24.95 | $6.91 |
| Short term investments | ||||
| Net receivables | $3.34 | $1.56 | ||
| Inventory | $9.46 | $12.35 | $13.64 | $13.32 |
| Total current assets | $25.29 | $30.1 | $47.77 | $31.34 |
| Long term investments | ||||
| Property, plant & equipment | $43.94 | $93.81 | $94.85 | $95.95 |
| Goodwill & intangible assets | $0.12 | $10.47 | $10.71 | $10.95 |
| Total noncurrent assets | $45.02 | $105.25 | $106.69 | $107.94 |
| Total investments | ||||
| Total assets | $70.31 | $135.34 | $154.46 | $139.28 |
| Current liabilities | ||||
| Accounts payable | $10.41 | $6.65 | $3.78 | $7.8 |
| Deferred revenue | ||||
| Short long term debt | $3.1 | $3.1 | $2.62 | $0.43 |
| Total current liabilities | $22.04 | $20.48 | $18.88 | $17.73 |
| Long term debt | $6.16 | $6.72 | $7.19 | $0.72 |
| Total noncurrent liabilities | $6.16 | $6.72 | $30.05 | $0.72 |
| Total debt | $9.26 | $9.82 | $9.81 | $1.15 |
| Total liabilities | $28.2 | $27.2 | $48.93 | $18.45 |
| Shareholders' equity | ||||
| Retained earnings | -$694.37 | -$615.6 | -$600.66 | -$573.34 |
| Other shareholder equity | -$0.24 | -$0.24 | -$0.23 | -$0.22 |
| Total shareholder equity | $42.1 | $108.14 | $105.53 | $120.83 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $24.95 | $120.23 | $178.9 | $77.31 |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | $13.64 | |||
| Total current assets | $47.77 | $130.78 | $189.05 | $87.99 |
| Long term investments | ||||
| Property, plant & equipment | $94.85 | $94.53 | $51.47 | $9.83 |
| Goodwill & intangible assets | $10.71 | $0.12 | $0.12 | |
| Total noncurrent assets | $106.69 | $94.91 | $51.85 | $10.19 |
| Total investments | ||||
| Total assets | $154.46 | $225.69 | $240.9 | $98.18 |
| Current liabilities | ||||
| Accounts payable | $3.78 | $8.07 | $13.28 | $4.6 |
| Deferred revenue | ||||
| Short long term debt | $2.62 | $0.43 | $0.49 | $0.59 |
| Total current liabilities | $18.88 | $18.18 | $21.72 | $9.82 |
| Long term debt | $7.19 | $0.33 | $0.47 | $0.72 |
| Total noncurrent liabilities | $30.05 | $0.33 | $0.47 | $0.72 |
| Total debt | $9.81 | $0.76 | $0.96 | $1.31 |
| Total liabilities | $48.93 | $18.51 | $22.18 | $10.54 |
| Shareholders' equity | ||||
| Retained earnings | -$600.66 | -$470.04 | -$359.82 | -$267.53 |
| Other shareholder equity | -$0.23 | -$0.17 | -$0.09 | -$0.06 |
| Total shareholder equity | $105.53 | $207.18 | $218.72 | $87.65 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2.21 | $2.48 | $3.78 | $3.99 |
| Cost of revenue | $3.37 | $1.66 | $2.37 | $2.37 |
| Gross Profit | -$1.16 | $0.82 | $1.41 | $1.61 |
| Operating activities | ||||
| Research & development | $9.7 | $12.86 | $17.12 | $21.05 |
| Selling, general & administrative | $7.5 | $9.31 | $11.62 | $8.71 |
| Total operating expenses | $76.16 | $22.17 | $28.74 | $29.76 |
| Operating income | -$77.32 | -$21.35 | -$27.33 | -$28.15 |
| Income from continuing operations | ||||
| EBIT | -$78.78 | -$14.94 | -$27.32 | -$27.98 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$78.78 | -$14.94 | -$27.32 | -$27.98 |
| Income (for common shares) | -$78.78 | -$14.94 | -$27.32 | -$27.98 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $7.77 | |||
| Cost of revenue | $4.74 | |||
| Gross Profit | $3.03 | |||
| Operating activities | ||||
| Research & development | $86.66 | $81.88 | $68.84 | $36.16 |
| Selling, general & administrative | $34.75 | $30.21 | $23.47 | $14.35 |
| Total operating expenses | $121.41 | $112.09 | $92.31 | $50.51 |
| Operating income | -$118.38 | -$112.09 | -$92.31 | -$50.51 |
| Income from continuing operations | ||||
| EBIT | -$116.66 | -$110.22 | -$92.29 | -$50.46 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$116.66 | -$110.22 | -$92.29 | -$50.46 |
| Income (for common shares) | -$116.66 | -$116.88 | -$92.29 | -$52.17 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Net income | -$78.78 | -$14.94 | -$27.32 | -$27.98 |
| Operating activities | ||||
| Depreciation | $1.21 | $1.21 | $1.26 | $1.22 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $1.15 | $1.69 | $2.04 | $2.08 |
| Total cash flows from operations | -$9.92 | -$17.57 | -$22.34 | -$23.39 |
| Investing activities | ||||
| Capital expenditures | -$0.11 | -$0.43 | -$0.82 | |
| Investments | ||||
| Total cash flows from investing | -$0.11 | -$0.43 | -$0.82 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $10.73 | $0.02 | $9.2 | $6.27 |
| Net borrowings | -$0.7 | -$0.23 | $8.94 | |
| Total cash flows from financing | $7.03 | -$0.21 | $40.71 | $6.27 |
| Effect of exchange rate | $0 | -$0 | -$0.01 | -$0.01 |
| Change in cash and equivalents | -$2.89 | -$17.9 | $17.93 | -$17.94 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$116.66 | -$110.22 | -$92.29 | -$50.46 |
| Operating activities | ||||
| Depreciation | $4.29 | $1.25 | $0.05 | $0.03 |
| Business acquisitions & disposals | -$22.17 | |||
| Stock-based compensation | $9.28 | $10.91 | $7.9 | $2.88 |
| Total cash flows from operations | -$102 | -$98.05 | -$75.56 | -$48.57 |
| Investing activities | ||||
| Capital expenditures | -$6.9 | -$48.15 | -$35.31 | -$8.56 |
| Investments | ||||
| Total cash flows from investing | -$29.07 | -$48.15 | -$35.31 | -$8.56 |
| Financing activities | ||||
| Dividends paid | $4.6 | |||
| Sale and purchase of stock | $5 | $94.5 | $212.49 | $118.5 |
| Net borrowings | $8.94 | |||
| Total cash flows from financing | $36.52 | $87.84 | $212.49 | $123.11 |
| Effect of exchange rate | -$0.07 | -$0.07 | -$0.03 | -$0.02 |
| Change in cash and equivalents | -$94.62 | -$58.43 | $101.59 | $65.96 |
News
Fundamentals
| Market cap | $1.47M |
|---|---|
| Enterprise value | $6.58M |
| Shares outstanding | 9.83M |
| Revenue | $12.46M |
|---|---|
| EBITDA | -$144.12M |
| EBIT | -$149.01M |
| Net Income | -$149.01M |
| Revenue Q/Q | InfinityT% |
| Revenue Y/Y | N/A |
| P/E ratio | -0.01 |
|---|---|
| EV/Sales | 0.53 |
| EV/EBITDA | -0.05 |
| EV/EBIT | -0.04 |
| P/S ratio | 0.12 |
| P/B ratio | 0.03 |
| Book/Share | 4.31 |
| Cash/Share | 0.42 |
| EPS | -$15.15 |
|---|---|
| ROA | -119.36% |
| ROE | -158.27% |
| Debt/Equity | 0.46 |
|---|---|
| Net debt/EBITDA | -0.17 |
| Current ratio | 1.15 |
| Quick ratio | 0.72 |